공시 • Dec 23
Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering. Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,500,000 공시 • May 08
Curative Biotechnology, Inc. has filed a Follow-on Equity Offering. Curative Biotechnology, Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock 공시 • Feb 01
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 1,333,333
Price\Range: $6
Discount Per Security: $0.42 공시 • Jan 06
Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study Curative Biotechnology Inc. announced that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD). 공시 • Nov 08
Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million. Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 1,333,333
Price\Range: $6 공시 • Nov 01
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million. Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,553,398
Price\Range: $5.15
Discount Per Security: $0.3605 공시 • Jun 17
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors Curative Biotechnology, Inc. announced that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc, a leader in protein degradation technology, along with three Celgene scientists, including David Stirling, co-founder of Celgene. In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for: Strategic and operational planning Capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals Investor relations and public relations. Mr. Zaslow helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Prior to founding BioTheryX, Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Mr. Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School. 공시 • May 13
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors Curative Biotechnology Inc. announced that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees. 공시 • Apr 16
Curative Biotechnology, Inc. has filed an IPO. Curative Biotechnology, Inc. has filed an IPO.
Security Name: Units
Security Type: Equity/Derivative Unit 공시 • Nov 25
Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular Degeneration Curative Biotechnology, Inc. announced the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations. As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory Practice (GLP) toxicology studies for an IND filing. Ocular tolerance includes observations at dosing, general clinical observations twice daily (evaluation of behavior/clinical signs with particular attention paid to the eyes), ophthalmic examinations by a board-certified veterinary ophthalmologist according to the modified Hackett-McDonald scoring scale, and ocular histopathology. 공시 • Feb 05
Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease Connectyx Technologies Holdings Group, Inc. announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD). The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD. 공시 • Nov 25
Connectyx Announces Appointment of Michael K. Fish to Board of Directors Connectyx Technologies Holdings Group, Inc. announced that it has added Michael K. Fish to their Board of Directors. Mr. Fish founded a Certified PublicAccounting firm in South Florida and possesses expertise in all areas of accounting, finance, and taxes for business including experience in the medical, wholesale, and professional services sectors. Mr. Fish has agreed to serve as the Chairman of the Audit Committee of the Board. 공시 • Oct 18
Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma Connectyx Technologies Holdings Group, Inc. announced that, it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.